L-Nix OZ Oral Suspension is a combination antimicrobial formulation containing Levofloxacin 125 mg and Ornidazole 125 mg per 5 ml, designed for the treatment of mixed bacterial and protozoal infections. Levofloxacin, a broad-spectrum fluoroquinolone antibiotic, exerts bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing DNA replication and transcription. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa through disruption of DNA synthesis. This dual-action suspension is indicated for infections caused by susceptible organisms, including respiratory tract infections, urinary tract infections, gastrointestinal infections, and certain protozoal infections such as amoebiasis and giardiasis. The oral suspension formulation facilitates ease of administration, particularly in pediatric and geriatric populations. Dosage should be individualized based on the severity of infection, patient age, renal function, and clinical response. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and those with central nervous system disorders. Potential adverse effects include gastrointestinal disturbances, hypersensitivity reactions, and, rarely, tendonitis or neuropathy. L-Nix OZ Oral Suspension should be used under medical supervision, ensuring adherence to recommended dosing to minimize resistance development and optimize therapeutic outcomes.